This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Search results
-
Office Depot E-Business (Abridged)
Venkataraman, S.; Bodily, Samuel E.; Cross, Tom; Chatterjee, SayanCase DARDEN-BP-0524-ECorporate GovernanceThis case is an excellent illustration of offline/online integration. Office Depot used its supply chain, systems integration, and existing offline channel strengths to overcome competitive online threats from pure Internet players and other office-products-category players. Students get to consider the critical strategic options for overall strategy, pricing, product line, promotion, and business integration.Starting at €8.20
-
Dunia Finance LLC (A), (B), and (C) - Teaching Note
Venkatesan, Rajkumar; Bodily, Samuel E.; Yemen, Gerry; Gibbs, SheaTeaching Note DARDEN-M-0842TN-EMarketingTeaching note for product M-0842Starting at €0.00
-
Fortis Industries, Inc. (C)
Moriarty, Rowland T., Jr.; Swartz, GordonCase HBS-511081-EMarketingDescribes whether the company adopts the price-flex policy described in the (A) and (B) cases.Starting at €5.74
-
Sistemas de proyección Barco (C)
Moriarty, Rowland T., Jr.; McQuade, KristaCase HBS-506S13MarketingActualizaciones Barco de proyección Sistemas (B).Starting at €5.74
-
Signode Industries, Inc. (C) (Spanish Version)
Moriarty, Rowland T., Jr.; Swartz, GordonCase HBS-509S09MarketingContinúa la discusión de la política de precios-flex descrito en el caso (A) y el caso (B).Starting at €5.74
-
Fortis Industries, Inc. (C) (Spanish Version)
Moriarty, Rowland T., Jr.; Swartz, GordonCase HBS-514S03MarketingDescribe si la empresa adopta la política de precios-flex se describe en el (A) y (B) de los casos.Starting at €5.74
-
Merck & Company: Product KL-798
Frey, Sherwood C. Jr.; Bodily, Samuel E.Case DARDEN-QA-0582-EDecision AnalysisMerck has been approached by a small biotech research firm with the proposal that Merck buy the rights to a new drug that promises to treat obesity and lower cholesterol. The drug is in the middle of phase I of the FDA approval process. Pat Harlow, the chief licensing officer, has been leading Merck's investigation team. A meeting is scheduled for tomorrow at which Merck's response to the offer will be drafted.Starting at €8.20
-
Airbus and Boeing: Superjumbo Decisions
Bodily, Samuel E.; Lichtendahl, Kenneth C. Jr.Case DARDEN-QA-0720-EDecision AnalysisSet in 1999, this case allows students to put themselves in the positions of both Airbus and Boeing as Boeing considered how to respond to Airbus's decision to announce its plans to proceed or not with the $10 billion development of the world's first commercial superjumbo jet, the Airbus A3XX. Boeing was considering a development effort to "stretch" its 747 jumbo jet into a larger superjumbo version, the 747-X. At the time, the two companies' wid...Starting at €8.20
-
Merck & Company: Product KL-798 (Spanish version)
Frey, Sherwood C. Jr.; Bodily, Samuel E.Case DARDEN-QA-0910Decision AnalysisEsta es una traducción al español de la versión del 14 de junio de 2016 del caso UVA-QA-0582. Merck ha sido contactado por una pequeña empresa de investigación en biotecnología con una propuesta para que Merck compre los derechos de un nuevo medicamento que promete tratar la obesidad y reducir el colesterol. El medicamento se encuentra en la mitad de la fase I del proceso de aprobación de la FDA. Pat Harlow, el director de licencias, ha estado al...Starting at €8.20
-
Kelly Solar - Teaching Note
Lipson, Marc L.; Bodily, Samuel E.; Lichtendahl, Kenneth C. Jr.Teaching Note DARDEN-F-1614TN-EFinanceTeaching note for product F-1614Starting at €0.00